Anti-JEV Recombinant Antibody (2B4) (CAT#: MRO-1162LC)

This product is a recombinant anti-Japanese encephalitis virus monoclonal antibody 2B4. 2B4 specifically targets JEV and can be potentially used in the treatment study and diagnosis of Japanese encephalitis virus infection.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA
IF

Figure 1 The mAb 2B4 recognized JEV-infected BHK-21 cells.

Figure 1 The mAb 2B4 recognized JEV-infected BHK-21 cells.

The cells were infected with JEV NJ-2008 strain. At 72 hpi, the cells were fixed and primed with mAb 2B4 (1) and rabbit polyclonal antibody (pAb) (2), respectively; uninfected BHK-21cells, CSFV-infected PK-15 cells, PRRSV-infected Marc-145cells, and PCV2-infected PK-15 cells were also primed with mAb 2B4 as the negative controls (3–6).

Fine mapping of a linear epitope on EDIII of Japanese encephalitis virus using a novel neutralizing monoclonal antibody

WB

Figure 2 Identification of mAb 2B4 binding to JEV viral proteins by ELISA and Western blot analyses.

Figure 2 Identification of mAb 2B4 binding to JEV viral proteins by ELISA and Western blot analyses.

mAb 2B4 reacted with both rEDIII and rMEP proteins and the results showed a single band, respectively.

Fine mapping of a linear epitope on EDIII of Japanese encephalitis virus using a novel neutralizing monoclonal antibody

ELISA

Figure 3 Identification of mAb 2B4 binding to JEV viral proteins by ELISA and Western blot analyses.

Figure 3 Identification of mAb 2B4 binding to JEV viral proteins by ELISA and Western blot analyses.

The ELISA data showed that mAb 2B4 had strong interactions with rEDIII and Rmep.

Fine mapping of a linear epitope on EDIII of Japanese encephalitis virus using a novel neutralizing monoclonal antibody

Neut

Figure 4 The PRNT result of mAb 2B4.

Figure 4 The PRNT result of mAb 2B4.

The data showed that a PRNT50 titer of mAb 2B4 was 0.5 g/mL.

Fine mapping of a linear epitope on EDIII of Japanese encephalitis virus using a novel neutralizing monoclonal antibody

Neut

Figure 5 The survival curve of mice in the analysis of mAb neutralization of JEV.

Figure 5 The survival curve of mice in the analysis of mAb neutralization of JEV.

The mice were monitored daily for 30 days. The survival percentages were shown and the numbers of mice (N) in each experimental group were shown in the legend to each panel. Each descent means one occurrence of death in mice. Survival curve comparisons were performed using Graphpad Prism 5.0 software statistical analysis.

Fine mapping of a linear epitope on EDIII of Japanese encephalitis virus using a novel neutralizing monoclonal antibody

ELISA

Figure 6 Identification of the displayed epitopes by the phage displayed peptide library.

Figure 6 Identification of the displayed epitopes by the phage displayed peptide library.

MAb recognition of clones selected from the phage displayed peptide library. Ten clones selected after three rounds of biopanning from phage display peptide library were tested for binding to mAb by phage ELISA. C1–C10 for binding to mAb 2B4; the anti-CSFV mAb WH303 served as a negative control.

Fine mapping of a linear epitope on EDIII of Japanese encephalitis virus using a novel neutralizing monoclonal antibody


Specifications

  • Host Species
  • Mouse
  • Type
  • Mouse Antibody
  • Specificity
  • Japanese encephalitis virus
  • Clone
  • 2B4
  • Applications
  • ELISA, WB, IF, Neut
  • Related Disease
  • Japanese encephalitis virus infection

Applications

  • Application Notes
  • The JEV antibody has been reported in applications of Enzyme-linked Immunosorbent Assay, Western Blot, Immunofluorescence, Neutralization.
    IF: 1:50
    WB: 5 μg/ml
    ELISA: 1:100

Target

  • Alternative Names
  • Japanese encephalitis virus; JEV

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone 2B4"

See other products for "JEV"

Recombinant Antibody

Mouse Antibody

CAT Product Name Application Type
MRO-1162LC-S(P) Anti-JEV Recombinant Antibody scFv Fragment (2B4) ELISA, WB Mouse Antibody
MRO-1162LC-F(E) Anti-JEV Recombinant Antibody Fab Fragment (2B4) ELISA, WB Mouse Antibody

Epitope-Specific Antibody

CAT Product Name Application Type
EPAF-0335LC Recombinant Mouse Anti-JEV Antibody (2H2) WB IgG3

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for MRO-1162LC. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare